JP2020532537A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020532537A5 JP2020532537A5 JP2020512453A JP2020512453A JP2020532537A5 JP 2020532537 A5 JP2020532537 A5 JP 2020532537A5 JP 2020512453 A JP2020512453 A JP 2020512453A JP 2020512453 A JP2020512453 A JP 2020512453A JP 2020532537 A5 JP2020532537 A5 JP 2020532537A5
- Authority
- JP
- Japan
- Prior art keywords
- car
- cancer
- immune cells
- medicament according
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 40
- 210000002865 immune cell Anatomy 0.000 claims 33
- 239000000556 agonist Substances 0.000 claims 29
- 102100023606 Retinoic acid receptor alpha Human genes 0.000 claims 26
- 108091008726 retinoic acid receptors α Proteins 0.000 claims 26
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 23
- 238000000034 method Methods 0.000 claims 17
- 102000003702 retinoic acid receptors Human genes 0.000 claims 16
- 108090000064 retinoic acid receptors Proteins 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 10
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 10
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 10
- 230000004069 differentiation Effects 0.000 claims 10
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 10
- 230000001939 inductive effect Effects 0.000 claims 10
- 239000012190 activator Substances 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 8
- 238000002619 cancer immunotherapy Methods 0.000 claims 6
- 208000009527 Refractory anemia Diseases 0.000 claims 5
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 claims 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 4
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 3
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 3
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 3
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 3
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 3
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 3
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 3
- 102000017578 LAG3 Human genes 0.000 claims 3
- 101150030213 Lag3 gene Proteins 0.000 claims 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 3
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 3
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 3
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 230000003467 diminishing effect Effects 0.000 claims 3
- 230000002708 enhancing effect Effects 0.000 claims 3
- 230000001024 immunotherapeutic effect Effects 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 231100000419 toxicity Toxicity 0.000 claims 3
- 230000001988 toxicity Effects 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 239000005711 Benzoic acid Substances 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 102100039282 Cytochrome P450 26A1 Human genes 0.000 claims 2
- 206010066476 Haematological malignancy Diseases 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- 101000745891 Homo sapiens Cytochrome P450 26A1 Proteins 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038270 Refractory anaemia with an excess of blasts Diseases 0.000 claims 2
- 208000033501 Refractory anemia with excess blasts Diseases 0.000 claims 2
- 208000032411 Refractory with Excess of Blasts Anemia Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 239000003098 androgen Substances 0.000 claims 2
- 235000010233 benzoic acid Nutrition 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 230000004060 metabolic process Effects 0.000 claims 2
- 208000016586 myelodysplastic syndrome with excess blasts Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- MUTNCGKQJGXKEM-UHFFFAOYSA-N tamibarotene Chemical group C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1NC(=O)C1=CC=C(C(O)=O)C=C1 MUTNCGKQJGXKEM-UHFFFAOYSA-N 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 125000006017 1-propenyl group Chemical group 0.000 claims 1
- PNAWUIKCVQSLFG-UHFFFAOYSA-N 4-[(4-chloro-3-hydroxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl)amino]-2,6-difluorobenzoic acid Chemical compound C1=C2C(C)(C)CCC(C)(C)C2=C(Cl)C(O)=C1C(=O)NC1=CC(F)=C(C(O)=O)C(F)=C1 PNAWUIKCVQSLFG-UHFFFAOYSA-N 0.000 claims 1
- -1 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl Chemical group 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 claims 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000007660 Residual Neoplasm Diseases 0.000 claims 1
- 229940096885 Retinoic acid receptor agonist Drugs 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 1
- 229960001467 bortezomib Drugs 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000000564 macroglobulinemia Diseases 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 230000002071 myeloproliferative effect Effects 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 1
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000001539 phagocyte Anatomy 0.000 claims 1
- 210000004500 stellate cell Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229950010130 tamibarotene Drugs 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762552814P | 2017-08-31 | 2017-08-31 | |
| US62/552,814 | 2017-08-31 | ||
| PCT/US2018/048876 WO2019046591A1 (en) | 2017-08-31 | 2018-08-30 | SELECTIVE RAR AGONISTS IN ASSOCIATION WITH IMMUNE MODULATORS IN ANTICANCER IMMUNOTHERAPY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020532537A JP2020532537A (ja) | 2020-11-12 |
| JP2020532537A5 true JP2020532537A5 (enExample) | 2021-10-07 |
Family
ID=65436409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020512453A Pending JP2020532537A (ja) | 2017-08-31 | 2018-08-30 | がん免疫治療法のための免疫調節物質と併せたｒａｒ選択的アゴニスト |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US10363272B2 (enExample) |
| EP (1) | EP3675843A4 (enExample) |
| JP (1) | JP2020532537A (enExample) |
| KR (1) | KR20200044889A (enExample) |
| CN (1) | CN111148514A (enExample) |
| AU (1) | AU2018326617B2 (enExample) |
| CA (1) | CA3073953A1 (enExample) |
| IL (1) | IL272971A (enExample) |
| MX (1) | MX2020002262A (enExample) |
| NZ (1) | NZ761401A (enExample) |
| SG (1) | SG11202001479RA (enExample) |
| WO (1) | WO2019046591A1 (enExample) |
| ZA (1) | ZA202001884B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009510114A (ja) | 2005-09-30 | 2009-03-12 | ビテ ファーマシューティカルズ， インコーポレイテッド | 特定のｒｘｒアゴニストによる癌治療 |
| US10653650B2 (en) | 2011-12-13 | 2020-05-19 | Io Therapeutics, Inc. | Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists |
| US20130190395A1 (en) | 2011-12-13 | 2013-07-25 | Dartmouth College | Autoimmune disorder treatment using rxr agonists |
| PL3368080T3 (pl) | 2015-10-31 | 2023-09-11 | Io Therapeutics, Inc. | Leczenie zaburzeń układu nerwowego z zastosowaniem kombinacji agonistów rxr i hormonów tarczycy |
| CN115227826A (zh) | 2016-03-10 | 2022-10-25 | Io治疗公司 | Rxr激动剂和甲状腺激素在制备用于治疗自身免疫疾病的药物中的用途 |
| SG11201807250PA (en) | 2016-03-10 | 2018-09-27 | Io Therapeutics Inc | Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones |
| WO2019014492A1 (en) | 2017-07-13 | 2019-01-17 | Io Therapeutics, Inc. | RETINOID COMPOUNDS AND IMMUNOMODULATORY REXINOIDS IN COMBINATION WITH IMMUNE MODULATORS FOR IMMUNOTHERAPY OF CANCER |
| JP2020532537A (ja) | 2017-08-31 | 2020-11-12 | アイオー セラピューティクス インコーポレイテッド | がん免疫治療法のための免疫調節物質と併せたｒａｒ選択的アゴニスト |
| AU2018335393A1 (en) | 2017-09-20 | 2020-04-02 | Io Therapeutics, Inc. | Treatment of disease with esters of selective RXR agonists |
| US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
| CN112390731B (zh) * | 2020-11-16 | 2022-11-25 | 成都大学 | 一种具有多靶点的维甲酸类衍生物及其制备方法与应用 |
| JP2024543621A (ja) | 2021-12-07 | 2024-11-21 | アイオー セラピューティクス インコーポレイテッド | Ｈｅｒ２＋がんの治療におけるｒｘｒアゴニストおよびタキサンの使用 |
| JP2024544223A (ja) | 2021-12-07 | 2024-11-28 | アイオー セラピューティクス インコーポレイテッド | Ｈｅｒ２＋がんの治療におけるｒｘｒアゴニストの使用 |
| AU2023301379A1 (en) | 2022-06-27 | 2024-12-19 | Io Therapeutics, Inc. | Synthesis of tetrahydronaphthalenols and uses thereof |
| KR102874422B1 (ko) | 2022-11-04 | 2025-10-22 | 한국원자력연구원 | 무정전 전원을 갖는 환경방사선 감시시스템의 전원 시스템 및 그 방법 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1576007A (en) | 1976-02-11 | 1980-10-01 | Beecham Group Ltd | Hypolipidaemic compositions |
| US4326055A (en) | 1977-12-22 | 1982-04-20 | Hoffmann-La Roche Inc. | Stilbene derivatives |
| US5234926A (en) | 1987-03-20 | 1993-08-10 | Allergan, Inc. | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity |
| US5324840A (en) | 1992-06-11 | 1994-06-28 | Allergan, Inc. | Method of treatment with compounds having retinoid-like activity and reduced skin toxicity and lacking teratogenic effects |
| ES2102195T3 (es) | 1992-12-28 | 1997-07-16 | Eisai Co Ltd | Derivados heterociclicos de acido carbonico que se fijan en receptores de retinoides. |
| CA2138000A1 (en) | 1994-01-03 | 1995-07-04 | John E. Starrett, Jr. | Retinoid-like compounds |
| US5824685A (en) | 1995-02-01 | 1998-10-20 | The Johns Hopkins University School Of Medicine | Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists |
| US5776699A (en) | 1995-09-01 | 1998-07-07 | Allergan, Inc. | Method of identifying negative hormone and/or antagonist activities |
| US6942980B1 (en) | 1995-09-01 | 2005-09-13 | Allergan, Inc. | Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities |
| US5958954A (en) | 1995-09-01 | 1999-09-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
| FR2739557B1 (fr) | 1995-10-09 | 1997-11-14 | Cird Galderma | Utilisation d'un ligand agoniste specifique rar-gamma |
| US5965606A (en) * | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
| US5877207A (en) | 1996-03-11 | 1999-03-02 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
| US5723666A (en) | 1996-06-21 | 1998-03-03 | Allergan | Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
| CA2263817A1 (en) | 1996-08-28 | 1998-03-05 | Centre National De La Recherche Scientifique | Therapeutic combinations of rar antagonists and rxr agonists and use thereof |
| US5739338A (en) | 1996-11-05 | 1998-04-14 | Allergan | N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity |
| US6037488A (en) | 1997-04-19 | 2000-03-14 | Allergan Sales, Inc. | Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity |
| US5919970A (en) | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
| AU774538B2 (en) | 1999-06-11 | 2004-07-01 | Allergan, Inc. | Organosilyl compounds having nuclear hormone receptor modulating activity |
| WO2001007028A2 (en) | 1999-07-23 | 2001-02-01 | Allergan Sales, Inc. | The use of retinoid receptor antagonists in the treatment of prostate carcinoma |
| TWI281911B (en) * | 2000-04-04 | 2007-06-01 | Allergan Inc | Treatment of tumors with RARalpha selective retinoid compounds in combination with other anti-tumor agents |
| JP4118675B2 (ja) | 2000-10-02 | 2008-07-16 | エフ．ホフマン−ラ ロシュ アーゲー | 気腫治療用新規レチノイド |
| EP1353217A1 (en) | 2002-03-29 | 2003-10-15 | JSR Corporation | Optical alignment method and liquid crystal display element |
| US7429596B2 (en) | 2003-06-20 | 2008-09-30 | The Regents Of The University Of California | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof |
| WO2005046726A2 (en) | 2003-11-12 | 2005-05-26 | Allergan, Inc. | Combinations for inhibiting cell growth which contains an inhibitor of human ck1 alpha activity and a rxr agonist |
| US7476673B2 (en) | 2003-12-30 | 2009-01-13 | Allergan, Inc. | Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors |
| EP1799812A4 (en) * | 2004-09-16 | 2009-09-09 | Gamida Cell Ltd | EX VIVO CULTIVATION METHODS OF STEM CELLS AND PRECURSOR BY CO-CULTURE WITH MESENCHYMAL CELLS |
| JP2009510114A (ja) | 2005-09-30 | 2009-03-12 | ビテ ファーマシューティカルズ， インコーポレイテッド | 特定のｒｘｒアゴニストによる癌治療 |
| DK2026778T3 (en) | 2006-05-16 | 2019-01-07 | Io Therapeutics Llc | RAR ANTAGONIST OR INVERSE AGONIST FOR USE IN THE TREATMENT OF CHEMOTHERAPY AND / OR RADIATION THERAPY SIDE EFFECTS |
| WO2008121570A1 (en) | 2007-03-29 | 2008-10-09 | Irm Llc | Compounds and methods for modulating g protein-coupled receptors |
| AR069747A1 (es) * | 2007-11-30 | 2010-02-17 | Medarex Inc | Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion |
| KR101577843B1 (ko) * | 2007-12-14 | 2015-12-16 | 브리스톨-마이어스 스큅 컴퍼니 | 인간 ｏｘ４０ 수용체에 대한 결합 분자 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| WO2011155607A1 (ja) * | 2010-06-11 | 2011-12-15 | 協和発酵キリン株式会社 | 抗ｔｉｍ－３抗体 |
| US10485780B2 (en) | 2011-03-14 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the treatment of proliferative disorders |
| US9446105B2 (en) * | 2013-03-15 | 2016-09-20 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor specific for folate receptor β |
| US9790282B2 (en) * | 2013-03-25 | 2017-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD276 polypeptides, proteins, and chimeric antigen receptors |
| CA2899577C (en) | 2013-04-03 | 2023-10-17 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| WO2015092420A1 (en) | 2013-12-20 | 2015-06-25 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
| WO2015138920A1 (en) * | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| CN106459063A (zh) | 2014-04-11 | 2017-02-22 | 北卡罗来纳-查佩尔山大学 | Mertk‑特异性嘧啶化合物 |
| WO2016015095A1 (en) | 2014-07-31 | 2016-02-04 | The University Of Western Australia | A method for the identification of immunotherapy-drug combinations using a network approach |
| AU2015315435A1 (en) | 2014-09-08 | 2017-03-23 | Celgene Corporation | Methods for treating a disease or disorder using oral formulations of cytidine analogs in combination with an anti-PD1 or anti-PDL1 monoclonal antibody |
| WO2016061142A1 (en) * | 2014-10-14 | 2016-04-21 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| JP6723164B2 (ja) | 2014-12-25 | 2020-07-15 | 株式会社癌免疫研究所 | Ｔ細胞集団の改変方法 |
| MA41414A (fr) * | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| EP3267969A1 (en) * | 2015-03-09 | 2018-01-17 | King's College London | Combination therapy with rar alpha agonists for enhancing th1 response |
| CA2986765A1 (en) * | 2015-05-29 | 2016-12-08 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
| EP3337514B8 (en) | 2015-08-18 | 2022-04-06 | Rakuten Medical, Inc. | Composition comprising a conjugate comprising a phthalocyanine dye linked to a targeting molecule for photoimmunotherapy |
| EP3344656A1 (en) * | 2015-09-01 | 2018-07-11 | Agenus Inc. | Anti-pd-1 antibodies and methods of use thereof |
| SG11201802966TA (en) | 2015-10-20 | 2018-05-30 | Kite Pharma Inc | Methods of preparing t cells for t cell therapy |
| PL3380086T3 (pl) * | 2015-11-25 | 2022-02-21 | Io Therapeutics, Inc. | Oporne na cyp26 agonisty selektywne względem rar-alfa w leczeniu nowotworu |
| EP3383908A1 (en) * | 2015-12-02 | 2018-10-10 | Stsciences, Inc. | Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator) |
| WO2017201200A1 (en) | 2016-05-19 | 2017-11-23 | Orphagen Pharmaceuticals, Inc. | Therapeutic compositions containing rar-alpha antagonists |
| KR20190017950A (ko) | 2016-06-10 | 2019-02-20 | 아이오 테라퓨틱스, 인크. | 암 면역요법을 위한 수용체 선택적 레티노이드 및 렉시노이드 화합물 및 면역 조절제 |
| WO2019014492A1 (en) | 2017-07-13 | 2019-01-17 | Io Therapeutics, Inc. | RETINOID COMPOUNDS AND IMMUNOMODULATORY REXINOIDS IN COMBINATION WITH IMMUNE MODULATORS FOR IMMUNOTHERAPY OF CANCER |
| JP2020532537A (ja) | 2017-08-31 | 2020-11-12 | アイオー セラピューティクス インコーポレイテッド | がん免疫治療法のための免疫調節物質と併せたｒａｒ選択的アゴニスト |
-
2018
- 2018-08-30 JP JP2020512453A patent/JP2020532537A/ja active Pending
- 2018-08-30 KR KR1020207008540A patent/KR20200044889A/ko not_active Ceased
- 2018-08-30 EP EP18852337.7A patent/EP3675843A4/en active Pending
- 2018-08-30 AU AU2018326617A patent/AU2018326617B2/en active Active
- 2018-08-30 CA CA3073953A patent/CA3073953A1/en active Pending
- 2018-08-30 NZ NZ761401A patent/NZ761401A/en unknown
- 2018-08-30 SG SG11202001479RA patent/SG11202001479RA/en unknown
- 2018-08-30 MX MX2020002262A patent/MX2020002262A/es unknown
- 2018-08-30 CN CN201880056488.6A patent/CN111148514A/zh active Pending
- 2018-08-30 US US16/117,372 patent/US10363272B2/en active Active
- 2018-08-30 WO PCT/US2018/048876 patent/WO2019046591A1/en not_active Ceased
-
2019
- 2019-06-26 US US16/452,800 patent/US10532073B2/en active Active
- 2019-07-23 US US16/519,544 patent/US10532074B2/en active Active
- 2019-12-12 US US16/711,627 patent/US10874694B2/en active Active
-
2020
- 2020-02-27 IL IL272971A patent/IL272971A/en unknown
- 2020-03-24 ZA ZA2020/01884A patent/ZA202001884B/en unknown
- 2020-12-16 US US17/123,577 patent/US11786555B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230310595A1 (en) | Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers | |
| JP2021183650A (ja) | 治療用組成物、組合せ物および使用の方法 | |
| KR102705821B1 (ko) | 항암제 | |
| JPWO2019124500A1 (ja) | Ｔｌｒ７アゴニストを含む併用薬 | |
| JP2017532372A5 (enExample) | ||
| RU2017112379A (ru) | Сочетанные способы лечения с использованием ингибиторов alk | |
| JP2018519327A5 (enExample) | ||
| Blaszczak et al. | Clinical value of monoclonal antibodies and tyrosine kinase inhibitors in the treatment of head and neck squamous cell carcinoma | |
| Lonez et al. | Celyad's novel CAR T-cell therapy for solid malignancies | |
| CN110996934A (zh) | 与免疫调节剂联合应用于癌症免疫治疗的受体亚型和功能选择性类视黄醇和rexinoid化合物 | |
| TW202039507A (zh) | 使用3,5-二取代苯炔基化合物與帕博利珠單抗之癌症治療法 | |
| JP7492752B2 (ja) | 免疫療法のためのアジュバントとしてのグアナベンズ | |
| JP7154634B2 (ja) | 腫瘍免疫賦活剤 | |
| Yang et al. | Targeting tumour-infiltrating B cells: mechanisms and advances in cancer therapy | |
| JP2022512539A5 (enExample) | ||
| JP7636322B2 (ja) | 癌を処置するためのマドラシン誘導体化合物、組成物およびこれらの使用 | |
| CN110891944B (zh) | 用于治疗癌症的化合物、组合物及其用途 | |
| Wu et al. | Viral immunotherapy: Oncolytic approaches for solid tumors | |
| HK40075828A (en) | Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers |